Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607414 | 0.97 | — | — | |
| Formic Acid SCHEMBL27145158 | 0.87 | PGD (0.37) | SLC22A6ALOX15TDP1SMN1; SMN2LMNA | |
| SCHEMBL2915579 | 0.77 | GAA (0.37) | SLC22A6GAAHTTRECQLTSHR | |
| SCHEMBL3238307 | 0.77 | GAA (0.34) | TDP1GAAHTTRECQLTSHR | |
| SCHEMBL6056743 | 0.76 | GAA (0.39) | GAAHTTRECQLMAPTMMP12 | |
| SCHEMBL2914706 | 0.75 | SLC22A6 (0.52) | SLC22A6TDP1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2914699 | 0.75 | SLC22A6 (0.52) | SLC22A6TDP1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3692336 | 0.74 | MMP12 (0.47) | SLC22A6ALOX15TDP1SMN1; SMN2LMNA | |
| SCHEMBL122205 | 0.74 | — | — | |
| SCHEMBL99435 | 0.72 | TSHR (0.48) | LMNAGAAHTTRECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1321107-C | Process for the preparatino of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER PROD INC (US) | 2007-06-13 | — | — | CN | disclosed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7186870-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| US-7091372-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2006-08-15 | — | — | US | disclosed |
| CN-1263745-C | Aryl fused azapolycyclic compounds | PFIZER PROD INC (US) | 2006-07-12 | — | — | CN | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| EP-1619192-A2 | Aryl fused azapolycyclic compounds | Pfizer Products Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| CN-1503781-A | Process for preparing 1, 3-substituted indenes and aryl-fused azapolycyclic compounds | �Ʒ� | 2004-06-09 | — | — | CN | disclosed |
| EP-1383733-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| CN-1406227-A | aryl fused azapolycyclic compounds | PFIZER PROD INC (US) | 2003-03-26 | — | — | CN | disclosed |
| EP-1259489-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002085843-A2 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001062736-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | SLC22A6 2338/4885ALOX15 2846/4885TDP1 1128/4885 |
| US-20060079707-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | CYP1B1, AZI2, CYP1A1 | SLC22A6 3780/4885ALOX15 2936/4885TDP1 2442/4885 |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | INTS6, CYP1B1, CYP1A2 | SLC22A6 4283/4885ALOX15 2626/4885TDP1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.